It costs Novo Nordisk less than $5 per month to produce its top-selling diabetes injection, Ozempic, even as it charges nearly $1,000 for a month’s supply before insurance, according to a new study.
The study, published Wednesday in the journal JAMA Network Open, raises questions about the prohibitive cost of the popular diabetes treatment and other weight loss drugs that belong to a pricy class of medications based on GLP-1 technology.
